Latest 

How to win the US: Alembic Pharma will have to crack the complex-products game

Pehal News Team 0 Comments


Alembic Pharmaceutical plant

Synopsis

Alembic Pharma’s heavy investments in America over the previous few years are set to carry returns, however the firm can’t afford to relaxation on its laurels. As it enters an uncharted territory of advanced merchandise, compliance dangers and uncertainties round approvals will enhance. How properly it navigates these challenges will decide its success.

In July 2018, the US Food and Drug Administration (USFDA) introduced a voluntary recall of a number of medication containing valsartan, used to deal with hypertension and coronary heart failure, due to presence of a cancer-causing impurity N-nitrosodimethylamine (NDMA). The USFDA mentioned that the presence of NDMA might be associated to adjustments in the manner the lively substance was manufactured. It grew to become a significant challenge as many pharmaceutical corporations, together with some

BY

  • GIFT ARTICLE
  • FONT SIZE

    AbcSmall

    AbcMedium

    AbcLarge

  • SAVE
  • COMMENT

Sign in to learn the full article

You’ve obtained this Prime Story as a Free Gift

Already a Member?

Special Offer on ET Prime

Subscribe to ET Prime – Get Flat 20% Off

View Plans

Special Offer on ET Prime

Subscribe & get 30% off on 2-Year Plan

View Plans

Special Offer on ET Prime

Subscribe & get 30% off on 2-Year Plan

View Plans

Why ?

  • Sharp Insight-rich, Indepth tales throughout 20+ sectors

  • Access the unique Economic Times tales, Editorial and Expert opinion

  • Clean expertise with
    Minimal Ads

  • Comment & Engage with ET Prime group

  • Exclusive invitations to Virtual Events with Industry Leaders

  • A trusted staff of Journalists & Analysts who can finest filter sign from noise



Source link

Post Views: 1